by Raynovich Rod | Dec 12, 2013 | Biopharmaceuticals
Biotech Bull Market Takes A Breather When the biotech bull market began in Q2 2009 it was value driven because of low technology values and Price/Sales for the widely covered stocks. Product sales were about to explode for many companies and in 2012 the sector took...
by Raynovich Rod | Nov 19, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
Bull Market Intact But Momentum Stocks Taking Hits Most of you know the game. Buy stocks with headline news, new business models, increasing RSI and charts that scream momentum. Examples proliferate: Aegerion (AEGR), Celldex (CLDX), Netflix (NFLX), Tesla (TSLA), 3D...
by Raynovich Rod | Oct 24, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Biotech Stocks Have Recovered From Early October Lows We have been traveling for two weeks and have not posted new content nor made portfolio changes. Despite a significant correction in the biotech sector in early October when major ETFs (IBB) and funds such as the...
by Raynovich Rod | Oct 9, 2013 | Biopharmaceuticals
Are Biotech Valuations in the “Bubblet” Phase? In September of 2013 we wrote about the valuations of biotechnology companies from an M&A perspective after the acquisition of Onyx Pharmaceuticals (ONXX) by Amgen at a price of $10.4B. We will attempt to...
by Raynovich Rod | Oct 7, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Our Indicators Flash a Caution Signal Today No Change in Portfolio Picks If you are not at 10% cash in your biotechnology portfolio it is time to take profits or hedge your portfolio. If your biotech stock did not hit a new high last week you may want to sell it. Risk...
by Raynovich Rod | Oct 3, 2013 | Biopharmaceuticals
Life Science Trading Update 10/4/13 NASDAQ up 0.88% at 3809 Is the market expecting Boehner to settle? Green screen today with most market leaders up about 2%: AMGN, BIIB, PCYC, REGN, VPHM. ETFs up in the 1% range. DX and Tools Movers: GHDX, ILMN. Mid and...
by Raynovich Rod | Mar 14, 2013 | Biopharmaceuticals, Macro
Technicals Matter in a MOmentum Market Some important trends are developing in momentum stocks some of which are on in our Life Science Portfolio. As we have written previously many momentum stocks are being driven by media buzz, novel business models and sponsorship...
